肝门胆管癌的放疗进展

国际肿瘤学杂志››2014,Vol. 41››Issue (5): 350-353.doi:10.3760/cma.j.issn.1673-422X.2014.05.010

郭剑洋,刘霞,廖锐,杜成友

400016 重庆医科大学附属第一医院肝胆外科

收稿日期:2013-12-23修回日期:2014-01-10出版日期:2014-05-08发布日期:2014-04-28
通讯作者:杜成友 E-mail:duchengyou@126.com
基金资助:

国家自然科学基金（81301656）

Progress of radiotherapy for hilar cholangiocarcinoma

Guo Jianyang, Liu Xia, Liao Rui, Du Chengyou

Department of Hepatobiliary Surgery, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China

Received:2013-12-23Revised:2014-01-10Online:2014-05-08Published:2014-04-28
Contact:Du Chengyou E-mail:duchengyou@126.com

摘要/Abstract

摘要：肝门胆管癌手术切除率及切净率均较低，极大地影响了疗效。放疗作为一种常用的恶性肿瘤治疗方式，对肝门胆管癌的运用有限。近年来随着放疗技术的发展，放疗与肝门胆管癌的研究成为热点。许多研究认为放疗作为手术辅助治疗或保守治疗，可提高肝门胆管癌患者生存期并改善其生存质量。

郭剑洋,刘霞,廖锐,杜成友. 肝门胆管癌的放疗进展[J]. 国际肿瘤学杂志, 2014, 41(5): 350-353.

Guo Jianyang, Liu Xia, Liao Rui, Du Chengyou. Progress of radiotherapy for hilar cholangiocarcinoma[J]. Journal of International Oncology, 2014, 41(5): 350-353.

［1］ Shi Z, Yang MZ, He QL, et a1. Addition of hepatectomy decreases liver reeurrenee and leads to long survival in hilar cholangiocareinoma［J］. World J Gastroenterol, 2009, 15(15):1892-1896. ［2］ Isayama H, Tsujino T, Nakai Y, et al. Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma［J］. World J Gastroenterol, 2012, 18(19):2364-2370. ［3］ Murakami Y, Uemura K, Sudo T, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma［J］. An Surg Oncol, 2011, 18(3):651-658. ［4］ Kim JY, Kang DH, Kim HW, et al. Usefulness of slimmer and opencelldesign stents for endoscopic bilateral stenting and endoscopic revision in patients with hilar cholangiocarcinoma (with video)［J］. Gastrointest Endosc, 2009, 70(6):1109-1115. ［5］ Minn AY, Koong AC, Chang DT. Stereotactic body radiation therapy for gastrointestinal malignancies［J］. Front Radiat Ther Oncol, 2011, 43:412-427. ［6］ Momm F, Schubert E, Henne K, et al. Stereotactic fractionated radiotherapy for Klatskin tumours［J］. Radiother Oncol, 2010, 95(1):99-102. ［7］ Polistina FA, Guglielmi R, Baiocchi C, et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, nonmetastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience［J］. Radiother Oncol, 2011, 99(2):120-123. ［8］ Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliarytract cancers and correlation of changes in 18fluorodeoxyglucose PET with clinical outcome: a phase 2 study［J］.Lancet Oncol, 2010, 11(1):48-54. ［9］ Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma［J］. An Surg, 2009, 250(6):950-956. ［10］ Patel T. Cholangiocarcinomacontroversies and challenges［J］. Nat Rev Gastroenterol Hepatol, 2011, 8(4):189-200. ［11］ Valero V 3rd, Cosgrove D, Herman JM, et al. Management of perihilar cholangiocarcinoma in the era of multimodal therapy［J］. Expert Rev Gastroenterol Hepatol, 2012, 6(4):481-495. ［12］ Murakami Y, Uemura K, Sudo T, et al. Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies［J］. J Gastrointest Surg, 2013, 17(8):1429-1439. ［13］ Salgia RJ, Singal AG, Fu S, et al. Improved posttransplant survival in the United States for patients with cholangiocarcinoma after 2000［J］. Dig Dis Sci, 2013, 16. ［14］ Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers［J］. Gastroenterology, 2012, 143(1):88-98. ［15］ Darwish Murad S, Heimbach JK, Gores GJ, et al. Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation［J］. Liver Transpl, 2013, 19(5):521-528. ［16］ Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment［J］. Hepatology, 2008, 48(1):308-321. ［17］ Hong JC, Petrowsky H, Kaldas FM, et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma［J］. J Am Coll Surg, 2011, 212(4):514-520. ［18］ Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24year experience in a single center［J］. Arch Surg, 2011, 146(6):683-689. ［19］ Zamboglou C, Messmer MB, Becker G, et al. Stereotactic radiotherapy in the liver hilum. Basis for future studies［J］. Strahlenther Onkol, 2012, 188(1):35-41.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[6]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[7]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[8]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[9]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[10]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[11]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[12]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[13]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[15]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.